Thank you for your question, Mr. Thériault.
First, you're entirely right to note the contradiction. It's obvious.
In fact, the PMPRB admits, through its actions and regulatory relief for vaccines, that its reform will indeed cause launch delays and problems. If it were consistent, it would continue this trend and do the same thing, which is to tighten price controls for vaccines as well. You're entirely right in saying that the fact it's currently loosening them is contradictory. That confirms what I'm saying.
You noted that the PMPRB hadn't even conducted an impact study to determine what consequences the regulatory reform might have on the life-sciences ecosystem. You're entirely right. I was able to lay my hands on only one simple—I'd even say simplistic—analysis. It's a correlation analysis involving a few variables and a number of countries, but no confounding factors. However, it's extremely important in science to have this type of study. Economists and other researchers in the social sciences will tell you it's very important, when you conduct this kind of study, to try to assess not only the correlation but also causal links. A study is virtually worthless without them.
Consequently, I'm not surprised there's been no impact study. The study I got my hands on isn't a very rigorous one for a public body such as the PMPRB.